Overview


According to FutureWise analysis the market for dermatology otc medication is expected to register a CAGR of 4.52% from 2023-2031.

In dermatology, diseases of nails, hair, skin, and common conditions such as psoriasis, acne, eczema, and acne vulgaris are treated. Hair, skin, and genital membrane diseases are treated and managed with dermatology drugs. OTC dermatology medicines can be purchased directly from the manufacturer without a prescription from a dermatologist, as opposed to prescription medications that are only sold to consumers with valid prescriptions. Rather than regulating final products, dermatology OTC drugs are usually regulated based on their active pharmaceutical ingredient. Dermatology OTC medications are increasingly used in the medical sector, which drives the market growth for dermatology OTC medications. Personal product expenditures are going up, people are becoming more aware of skin diseases, and the number of patients suffering from dermatitis, acne, and vitiligo is increasing. The young generation is aware of products that are effective to cure skin disorders and infections, and the growing number of companies manufacturing OTC medications for dermatological treatments are other factors driving the market for dermatology OTC medications. A dermatology over-the-counter (OTC) drug is one that can be purchased without a prescription from a healthcare professional, unlike a prescription drug, which can only be purchased with a valid prescription. A regulatory agency in many countries ensures that OTC drugs contain ingredients that are safe and effective when used without a physician's supervision. A wide range of skin diseases are treated with these medications, including dermatitis, acne, psoriasis, warts, and fungal infections. Acne is commonly treated with dermatology OTC medications. In order to develop effective and targeted acne control therapies, it is crucial to understand the characteristics of acne vulgaris burden. Dermatological pharmaceuticals market development is driven by the loss of human skin's ability to function properly with ageing, resulting in numerous skin diseases. Furthermore, as we age, the body experiences several additional issues, including slower wound healing, increased sensitivity to ultraviolet radiation, increased susceptibility to infections, and decreased subcutaneous fat. The prevalence of numerous skin conditions has resulted in an increase in the need for dermatological medications.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Dermatology OTC Medication Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Dermatology OTC Medication Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Bayer AG
  • Aurobindo Pharma
  • Cipla Inc
  • Galderma
  • GlaxoSmithKline Plc
  • Lupin Pharmaceuticals
  • Mylan N.V.
  • Novartis AG
  • Sun Pharmaceuticals
  • Teva Pharmaceuticals

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Type

  • Tablets and Capsules
  • Oils Gels
  • Creams and Ointments
  • Others

By Indication

  • Dermatitis
  • Acne
  • Psoriasis
  • Skin Bleaching
  • Anti-Fungal
  • Wart Remover
  • Others

By Route of Administration

  • Topical
  • Oral

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Dermatology OTC Medication Market By Type, By Indication, By Route of Administration and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Dermatology OTC Medication Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Dermatology OTC Medication Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Dermatology OTC Medication Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Dermatology OTC Medication Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Tablets and Capsules
        2. Oils Gels
        3. Creams and Ointments
        4. Others

  • 8.   Dermatology OTC Medication Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Dermatitis
        2. Acne
        3. Psoriasis
        4. Skin Bleaching
        5. Anti-Fungal
        6. Wart Remover
        7. Others

  • 9.   Dermatology OTC Medication Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Topical
        2. Oral

  • 10.   North America Dermatology OTC Medication Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Dermatology OTC Medication Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Dermatology OTC Medication Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Dermatology OTC Medication Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Bayer AG
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Aurobindo Pharma
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Cipla Inc
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Galderma
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. GlaxoSmithKline Plc
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Lupin Pharmaceuticals
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Mylan N.V.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Novartis AG
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Sun Pharmaceuticals
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Teva Pharmaceuticals
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients